Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management

Marker Therapeutics (NASDAQ:MRKR) was upgraded by equities researchers at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Separately, LADENBURG THALM/SH SH boosted their target price on Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Stock Performance

Shares of NASDAQ:MRKR opened at $1.55 on Monday. The stock’s 50-day moving average is $2.92 and its 200 day moving average is $3.25. Marker Therapeutics has a 1 year low of $1.55 and a 1 year high of $5.99.

Insider Transactions at Marker Therapeutics

In other news, Director Steve Elms purchased 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, with a total value of $35,472.00. Following the completion of the purchase, the director now directly owns 325,370 shares in the company, valued at approximately $1,041,184. This trade represents a 3.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the transaction, the insider now directly owns 1,625,678 shares of the company’s stock, valued at approximately $5,202,169.60. This trade represents a 51.73 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. LPL Financial LLC acquired a new stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 79,730 shares of the company’s stock, valued at approximately $248,000. LPL Financial LLC owned about 0.74% of Marker Therapeutics at the end of the most recent quarter. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.